Persistent uncertainties in optimal treatment approaches of secondary hyperparathyroidism and hyperphosphatemia in patients with chronic kidney disease
- 19.08.2024
- REVIEW
- Verfasst von
- Daniela Del Pilar Via Reque Cortes
- Tilman B. Drueke
- Rosa Maria Affonso Moysés
- Erschienen in
- Current Osteoporosis Reports | Ausgabe 5/2024
Abstract
Purpose of Review
This review is a critical analysis of treatment results obtained in clinical trials conducted in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), hyperphosphatemia, or both.
Recent Findings
Patients with CKD have a high mortality rate. The disorder of mineral and bone metabolism (CKD-MBD), which is commonly present in these patients, is associated with adverse outcomes, including cardiovascular events and mortality. Clinical trials aimed at improving these outcomes by modifying CKD-MBD associated factors have most often resulted in disappointing results. The complexity of CKD-MBD, where many players are closely interconnected, might explain these negative findings.
Summary
We first present an historical perspective of current knowledge in the field of CKD-MBD and then examine potential flaws of past and ongoing clinical trials targeting SHPT and hyperphosphatemia respectively in patients with CKD.
Anzeige
- Titel
- Persistent uncertainties in optimal treatment approaches of secondary hyperparathyroidism and hyperphosphatemia in patients with chronic kidney disease
- Verfasst von
-
Daniela Del Pilar Via Reque Cortes
Tilman B. Drueke
Rosa Maria Affonso Moysés
- Publikationsdatum
- 19.08.2024
- Verlag
- Springer US
- Erschienen in
-
Current Osteoporosis Reports / Ausgabe 5/2024
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241 - DOI
- https://doi.org/10.1007/s11914-024-00881-3
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.